Mesoridazine

Mesoridazine
Clinical data
Trade names Serentil
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a682306
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		 Oral, intravenous
    ATC code
    Legal status
    Legal status
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Protein binding 4%
    Metabolism Hepatic/renal
    Elimination half-life 24 to 48 hours
    Excretion Biliary and renal
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    Chemical and physical data
    Formula C21H26N2OS2
    Molar mass 386.576 g/mol
    3D model (JSmol)
    Melting point 130 °C (266 °F)
    Solubility in water insoluble mg/mL (20 °C)
      (verify)

    Mesoridazine (Serentil) is a piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia. It is a metabolite of thioridazine. The drug's name is derived from the methylsulfoxy and piperidine functional groups in its chemical structure.

    It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.

    Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome.

    Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.[1]

    It currently appears to be unavailable worldwide.

    References

    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.